1,367 results on '"Adler, Charles H."'
Search Results
2. Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project
- Author
-
van Amerongen, Suzan, Pulukuri, Surya V., Tuz-Zahra, Fatima, Tripodis, Yorghos, Cherry, Jonathan D., Bernick, Charles, Geda, Yonas E., Wethe, Jennifer V., Katz, Douglas I., Alosco, Michael L., Adler, Charles H., Balcer, Laura J., Ashton, Nicholas J., Blennow, Kaj, Zetterberg, Henrik, Daneshvar, Daniel H., Colasurdo, Elizabeth A., Iliff, Jeffrey J., Li, Gail, Peskind, Elaine R., Shenton, Martha E., Reiman, Eric M., Cummings, Jeffrey L., and Stern, Robert A.
- Published
- 2024
- Full Text
- View/download PDF
3. Biochemical analyses of tau and other neuronal markers in the submandibular gland and frontal cortex across stages of Alzheimer disease
- Author
-
Hamsafar, Yamah, Chen, Qian, Borowsky, Alexander D, Beach, Thomas G, Serrano, Geidy E, Sue, Lucia I, Adler, Charles H, Walker, Douglas G, and Dugger, Brittany N
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Acquired Cognitive Impairment ,Neurosciences ,Dementia ,Aging ,Neurodegenerative ,Brain Disorders ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Alzheimer's Disease ,2.1 Biological and endogenous factors ,Neurological ,Humans ,Alzheimer Disease ,Submandibular Gland ,tau Proteins ,Neurofibrillary Tangles ,Neurons ,Frontal Lobe ,Phosphorylation ,Submandibular gland ,Big tau ,4a exon ,Tau ,Phosphorylated tau ,Tyrosine hydroxylase ,Neurofilament heavy chain ,Microtubule-associated protein 2 ,Psychology ,Cognitive Sciences ,Biochemistry and cell biology ,Biological psychology - Abstract
Hyperphosphorylation of the microtubule-associated protein tau is hypothesized to lead to the development of neurofibrillary tangles in select brain regions during normal aging and in Alzheimer disease (AD). The distribution of neurofibrillary tangles is staged by its involvement starting in the transentorhinal regions of the brain and in final stages progress to neocortices. However, it has also been determined neurofibrillary tangles can extend into the spinal cord and select tau species are found in peripheral tissues and this may be depended on AD disease stage. To further understand the relationships of peripheral tissues to AD, we utilized biochemical methods to evaluate protein levels of total tau and phosphorylated tau (p-tau) as well as other neuronal proteins (i.e., tyrosine hydroxylase (TH), neurofilament heavy chain (NF-H), and microtubule-associated protein 2 (MAP2)) in the submandibular gland and frontal cortex of human cases across different clinicopathological stages of AD (n = 3 criteria not met or low, n = 6 intermediate, and n = 9 high likelihood that dementia is due to AD based on National Institute on Aging-Reagan criteria). We report differential protein levels based on the stage of AD, anatomic specific tau species, as well as differences in TH and NF-H. In addition, exploratory findings were made of the high molecular weight tau species big tau that is unique to peripheral tissues. Although sample sizes were small, these findings are, to our knowledge, the first comparison of these specific protein changes in these tissues.
- Published
- 2023
4. Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players
- Author
-
Alosco, Michael L, Su, Yi, Stein, Thor D, Protas, Hillary, Cherry, Jonathan D, Adler, Charles H, Balcer, Laura J, Bernick, Charles, Pulukuri, Surya Vamsi, Abdolmohammadi, Bobak, Coleman, Michael J, Palmisano, Joseph N, Tripodis, Yorghos, Mez, Jesse, Rabinovici, Gil D, Marek, Kenneth L, Beach, Thomas G, Johnson, Keith A, Huber, Bertrand Russell, Koerte, Inga, Lin, Alexander P, Bouix, Sylvain, Cummings, Jeffrey L, Shenton, Martha E, Reiman, Eric M, McKee, Ann C, and Stern, Robert A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Aging ,Physical Injury - Accidents and Adverse Effects ,Acquired Cognitive Impairment ,Brain Disorders ,Alzheimer's Disease ,Dementia ,Neurosciences ,Neurodegenerative ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Neurological ,Humans ,Alzheimer Disease ,Autopsy ,Brain ,Brain Injuries ,Traumatic ,Chronic Traumatic Encephalopathy ,Death ,Football ,Positron-Emission Tomography ,tau Proteins ,Biomarkers ,Chronic traumatic encephalopathy ,Neurodegenerative disease ,Positron emission tomography imaging ,Repetitive head impacts ,Tau ,Flortaucipir ,DIAGNOSE C. T. E. Research Project ,Other Physical Sciences ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
PurposeFlourine-18-flortaucipir tau positron emission tomography (PET) was developed for the detection for Alzheimer's disease. Human imaging studies have begun to investigate its use in chronic traumatic encephalopathy (CTE). Flortaucipir-PET to autopsy correlation studies in CTE are needed for diagnostic validation. We examined the association between end-of-life flortaucipir PET and postmortem neuropathological measurements of CTE-related tau in six former American football players.MethodsThree former National Football League players and three former college football players who were part of the DIAGNOSE CTE Research Project died and agreed to have their brains donated. The six players had flortaucipir (tau) and florbetapir (amyloid) PET prior to death. All brains from the deceased participants were neuropathologically evaluated for the presence of CTE. On average, the participants were 59.0 (SD = 9.32) years of age at time of PET. PET scans were acquired 20.33 (SD = 13.08) months before their death. Using Spearman correlation analyses, we compared flortaucipir standard uptake value ratios (SUVRs) to digital slide-based AT8 phosphorylated tau (p-tau) density in a priori selected composite cortical, composite limbic, and thalamic regions-of-interest (ROIs).ResultsFour brain donors had autopsy-confirmed CTE, all with high stage disease (n = 3 stage III, n = 1 stage IV). Three of these four met criteria for the clinical syndrome of CTE, known as traumatic encephalopathy syndrome (TES). Two did not have CTE at autopsy and one of these met criteria for TES. Concomitant pathology was only present in one of the non-CTE cases (Lewy body) and one of the CTE cases (motor neuron disease). There was a strong association between flortaucipir SUVRs and p-tau density in the composite cortical (ρ = 0.71) and limbic (ρ = 0.77) ROIs. Although there was a strong association in the thalamic ROI (ρ = 0.83), this is a region with known off-target binding. SUVRs were modest and CTE and non-CTE cases had overlapping SUVRs and discordant p-tau density for some regions.ConclusionsFlortaucipir-PET could be useful for detecting high stage CTE neuropathology, but specificity to CTE p-tau is uncertain. Off-target flortaucipir binding in the hippocampus and thalamus complicates interpretation of these associations. In vivo biomarkers that can detect the specific p-tau of CTE across the disease continuum are needed.
- Published
- 2023
5. Peripheral tau as a biomarker for neurodegenerative diseases: is life on Earth, life on Mars?
- Author
-
Dugger, Brittany N, Harvey, Danielle, Beach, Thomas G, and Adler, Charles H
- Subjects
Biomedical and Clinical Sciences ,Health Sciences ,Psychology ,Aging ,Acquired Cognitive Impairment ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Neurodegenerative ,Frontotemporal Dementia (FTD) ,Alzheimer's Disease Related Dementias (ADRD) ,Neurosciences ,Brain Disorders ,Alzheimer's Disease ,Dementia ,Neurological ,Good Health and Well Being ,Biomarkers ,Biopsy ,Humans ,Neurodegenerative Diseases ,Synucleinopathies ,Tauopathies ,tau Proteins ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery ,Biomedical and clinical sciences ,Health sciences - Abstract
This scientific commentary refers to ‘Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies’ by Vacchi et al. (https://doi.org/10.1093/brain/awac161).
- Published
- 2022
6. Resting-state EEG predicts cognitive decline in a neuropathologically diagnosed longitudinal community autopsied cohort
- Author
-
Choi, Alexander, Zhang, Nan, Adler, Charles H., Beach, Thomas G., Shill, Holly A., Driver-Dunckley, Erika, Mehta, Shyamal, Belden, Christine, Atri, Alireza, Sabbagh, Marwan N., and Caviness, John N.
- Published
- 2024
- Full Text
- View/download PDF
7. Level I PD‐MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia
- Author
-
Boel, Judith A, de Bie, Rob MA, Schmand, Ben A, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Goldman, Jennifer G, Tröster, Alexander I, Burn, David J, Litvan, Irene, Geurtsen, Gert J, Bernard, Bryan, Stebbins, Glenn, Filoteo, J Vincent, Weintraub, Daniel, Caviness, John N, Belden, Christine, Zabetian, Cyrus P, Cholerton, Brenna A, Huang, Xuemei, Eslinger, Paul J, Leverenz, James B, Duff‐Canning, Sarah, Farrer, Matt, Anderson, Tim J, Myall, Daniel J, Naismith, Sharon L, Lewis, Simon JG, Halliday, Glenda M, Wu, Ruey‐Meei, Williams‐Gray, Caroline H, Breen, David P, Barker, Roger A, Yarnall, Alison J, Klein, Martin, Mollenhauer, Brit, Trenkwalder, Claudia, Kulisevsky, Jaime, Pagonabarraga, Javier, Gasca‐Salas, Carmen, Rodriguez‐Oroz, Maria C, Junque, Carme, Segura, Barbara, Barone, Paolo, Santangelo, Gabriella, Cammisuli, Davide M, Biundo, Roberta, Antonini, Angelo, Weis, Luca, Pedersen, Kenn Freddy, and Alves, Guido
- Subjects
Acquired Cognitive Impairment ,Neurodegenerative ,Neurosciences ,Parkinson's Disease ,Dementia ,Clinical Research ,Aging ,Brain Disorders ,Neurological ,dementia ,mild cognitive impairment ,global cognitive tests ,Parkinson's disease ,diagnostic accuracy ,MDS Study Group Mild Cognitive Impairment in Parkinson's Disease - Abstract
BackgroundThe criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown.MethodsThe MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD.ResultsPD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P =
- Published
- 2022
8. RNA sequencing of olfactory bulb in Parkinson's disease reveals gene alterations associated with olfactory dysfunction
- Author
-
Tremblay, Cécilia, Aslam, Sidra, Walker, Jessica E., Lorenzini, Ileana, Intorcia, Anthony J., Arce, Richard A., Choudhury, Parichita, Adler, Charles H., Shill, Holly A., Driver-Dunckley, Erika, Mehta, Shyamal, Piras, Ignazio S., Belden, Christine M., Atri, Alireza, Beach, Thomas G., and Serrano, Geidy E.
- Published
- 2024
- Full Text
- View/download PDF
9. Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project
- Author
-
Stern, Robert A., Trujillo-Rodriguez, Diana, Tripodis, Yorghos, Pulukuri, Surya V., Alosco, Michael L., Adler, Charles H., Balcer, Laura J., Bernick, Charles, Baucom, Zachary, Marek, Kenneth L., McClean, Michael D., Johnson, Keith A., McKee, Ann C., Stein, Thor D., Mez, Jesse, Palmisano, Joseph N., Cummings, Jeffrey L., Shenton, Martha E., and Reiman, Eric M.
- Published
- 2023
- Full Text
- View/download PDF
10. Neuropsychological test performance of former American football players
- Author
-
Alosco, Michael L., Barr, William B., Banks, Sarah J., Wethe, Jennifer V., Miller, Justin B., Pulukuri, Surya Vamsi, Culhane, Julia, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J., Bernick, Charles, Mariani, Megan L., Cantu, Robert C., Dodick, David W., McClean, Michael D., Au, Rhoda, Mez, Jesse, Turner, II, Robert W., Palmisano, Joseph N., Martin, Brett, Hartlage, Kaitlin, Cummings, Jeffrey L., Reiman, Eric M., Shenton, Martha E., and Stern, Robert A.
- Published
- 2023
- Full Text
- View/download PDF
11. Symmetry of synuclein density in autopsied Parkinson’s disease submandibular glands
- Author
-
Adler, Charles H., Serrano, Geidy E., Shill, Holly A., Driver-Dunckley, Erika, Mehta, Shyamal H., Zhang, Nan, Glass, Michael, Sue, Lucia I., Intorcia, Anthony, and Beach, Thomas G.
- Published
- 2024
- Full Text
- View/download PDF
12. Examination of parkinsonism in former elite American football players
- Author
-
Alosco, Michael L., Adler, Charles H., Dodick, David W., Tripodis, Yorghos, Balcer, Laura J., Bernick, Charles, Banks, Sarah J., Barr, William B., Wethe, Jennifer V., Palmisano, Joseph N., Martin, Brett, Hartlage, Kaitlin, Cantu, Robert C., Geda, Yonas E., Katz, Douglas I., Mez, Jesse, Cummings, Jeffery L., Shenton, Martha E., Reiman, Eric M., and Stern, Robert A.
- Published
- 2024
- Full Text
- View/download PDF
13. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria
- Author
-
Höglinger, Günter U, Adler, Charles H, Berg, Daniela, Klein, Christine, Outeiro, Tiago F, Poewe, Werner, Postuma, Ronald, Stoessl, A Jon, and Lang, Anthony E
- Published
- 2024
- Full Text
- View/download PDF
14. Correction to: α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy
- Author
-
Dutta, Suman, Hornung, Simon, Kruayatidee, Adira, Maina, Katherine N, del Rosario, Irish, Paul, Kimberly C, Wong, Darice Y, Duarte Folle, Aline, Markovic, Daniela, Palma, Jose-Alberto, Serrano, Geidy E, Adler, Charles H, Perlman, Susan L, Poon, Wayne W, Kang, Un Jung, Alcalay, Roy N, Sklerov, Miriam, Gylys, Karen H, Kaufmann, Horacio, Fogel, Brent L, Bronstein, Jeff M, Ritz, Beate, and Bitan, Gal
- Subjects
Neurological ,Clinical Sciences ,Neurosciences ,Neurology & Neurosurgery - Abstract
A correction to this paper has been published: https://doi.org/10.1007/s00401-021-02332-0.
- Published
- 2021
15. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy
- Author
-
Dutta, Suman, Hornung, Simon, Kruayatidee, Adira, Maina, Katherine N, del Rosario, Irish, Paul, Kimberly C, Wong, Darice Y, Duarte Folle, Aline, Markovic, Daniela, Palma, Jose-Alberto, Serrano, Geidy E, Adler, Charles H, Perlman, Susan L, Poon, Wayne W, Kang, Un Jung, Alcalay, Roy N, Sklerov, Miriam, Gylys, Karen H, Kaufmann, Horacio, Fogel, Brent L, Bronstein, Jeff M, Ritz, Beate, and Bitan, Gal
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Brain Disorders ,Parkinson's Disease ,Aging ,Neurosciences ,Neurodegenerative ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Adult ,Aged ,Aged ,80 and over ,Area Under Curve ,Biomarkers ,Cohort Studies ,Diagnosis ,Differential ,Enzyme-Linked Immunosorbent Assay ,Exosomes ,Female ,Healthy Volunteers ,Humans ,Immunoprecipitation ,Male ,Middle Aged ,Multiple System Atrophy ,Neurons ,Oligodendroglia ,Parkinson Disease ,Reproducibility of Results ,Sensitivity and Specificity ,alpha-Synuclein ,Biomarker ,Extracellular vesicles ,Synucleinopathy ,Biofluid ,Neurology & Neurosurgery - Abstract
The diagnosis of Parkinson's disease (PD) and atypical parkinsonian syndromes is difficult due to the lack of reliable, easily accessible biomarkers. Multiple system atrophy (MSA) is a synucleinopathy whose symptoms often overlap with PD. Exosomes isolated from blood by immunoprecipitation using CNS markers provide a window into the brain's biochemistry and may assist in distinguishing between PD and MSA. Thus, we asked whether α-synuclein (α-syn) in such exosomes could distinguish among healthy individuals, patients with PD, and patients with MSA. We isolated exosomes from the serum or plasma of these three groups by immunoprecipitation using neuronal and oligodendroglial markers in two independent cohorts and measured α-syn in these exosomes using an electrochemiluminescence ELISA. In both cohorts, α-syn concentrations were significantly lower in the control group and significantly higher in the MSA group compared to the PD group. The ratio between α-syn concentrations in putative oligodendroglial exosomes compared to putative neuronal exosomes was a particularly sensitive biomarker for distinguishing between PD and MSA. Combining this ratio with the α-syn concentration itself and the total exosome concentration, a multinomial logistic model trained on the discovery cohort separated PD from MSA with an AUC = 0.902, corresponding to 89.8% sensitivity and 86.0% specificity when applied to the independent validation cohort. The data demonstrate that a minimally invasive blood test measuring α-syn in blood exosomes immunoprecipitated using CNS markers can distinguish between patients with PD and patients with MSA with high sensitivity and specificity. Future optimization and validation of the data by other groups would allow this strategy to become a viable diagnostic test for synucleinopathies.
- Published
- 2021
16. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.
- Author
-
Gupta, Harsh V, Beach, Thomas G, Mehta, Shyamal H, Shill, Holly A, Driver-Dunckley, Erika, Sabbagh, Marwan N, Belden, Christine M, Liebsack, Carolyn, Dugger, Brittany N, Serrano, Geidy E, Sue, Lucia I, Siderowf, Andrew, Pontecorvo, Michael J, Mintun, Mark A, Joshi, Abhinay D, and Adler, Charles H
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Clinical Sciences ,Neurosciences ,Psychology ,Alzheimer's Disease ,Neurodegenerative ,Brain Disorders ,Aging ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Acquired Cognitive Impairment ,Dementia ,Lewy Body Dementia ,Biomedical Imaging ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Neurological ,Aged ,Aged ,80 and over ,Alzheimer Disease ,Amyloid ,Aniline Compounds ,Dopamine ,Ethylene Glycols ,Fatal Outcome ,Female ,Fluorine Radioisotopes ,Humans ,Lewy Body Disease ,Male ,Middle Aged ,Plaque ,Amyloid ,Positron-Emission Tomography ,Radiopharmaceuticals ,Tetrabenazine ,Alzheimer's disease ,amyloid ,AV-133 ,dementia with Lewy bodies ,synucleinopathy ,VMAT2 ,Alzheimer’s disease ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
BackgroundImaging biomarkers have the potential to distinguish between different brain pathologies based on the type of ligand used with PET. AV-45 PET (florbetapir, Amyvid™) is selective for the neuritic plaque amyloid of Alzheimer's disease (AD), while AV-133 PET (florbenazine) is selective for VMAT2, which is a dopaminergic marker.ObjectiveTo report the clinical, AV-133 PET, AV-45 PET, and neuropathological findings of three clinically diagnosed dementia patients who were part of the Avid Radiopharmaceuticals AV133-B03 study as well as the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND).MethodsThree subjects who had PET imaging with both AV-133 and AV-45 as well as a standardized neuropathological assessment were included. The final clinical, PET scan, and neuropathological diagnoses were compared.ResultsThe clinical and neuropathological diagnoses were made blinded to PET scan results. The first subject had a clinical diagnosis of dementia with Lewy bodies (DLB); AV-133 PET showed bilateral striatal dopaminergic degeneration, and AV-45 PET was positive for amyloid. The final clinicopathological diagnosis was DLB and AD. The second subject was diagnosed clinically with probable AD; AV-45 PET was positive for amyloid, while striatal AV-133 PET was normal. The final clinicopathological diagnosis was DLB and AD. The third subject had a clinical diagnosis of DLB. Her AV-45 PET was positive for amyloid and striatal AV-133 showed dopaminergic degeneration. The final clinicopathological diagnosis was multiple system atrophy and AD.ConclusionPET imaging using AV-133 for the assessment of striatal VMAT2 density may help distinguish between AD and DLB. However, some cases of DLB with less-pronounced nigrostriatal dopaminergic neuronal loss may be missed.
- Published
- 2021
17. Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.
- Author
-
Adler, Charles H, Beach, Thomas G, Zhang, Nan, Shill, Holly A, Driver-Dunckley, Erika, Caviness, John N, Mehta, Shyamal H, Sabbagh, Marwan N, Serrano, Geidy E, Sue, Lucia I, Belden, Christine M, Powell, Jessica, Jacobson, Sandra A, Zamrini, Edward, Shprecher, David, Davis, Kathryn J, Dugger, Brittany N, and Hentz, Joseph G
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Dementia ,Aging ,Neurodegenerative ,Clinical Research ,Parkinson's Disease ,Acquired Cognitive Impairment ,Brain Disorders ,Neurological ,Aged ,Aged ,80 and over ,Brain ,Cognitive Dysfunction ,Female ,Humans ,Lewy Bodies ,Lewy Body Disease ,Male ,Severity of Illness Index ,alpha-Synuclein ,a-Synuclein ,Braak staging system ,Dementia with Lewy bodies ,Incidental Lewy body disease ,Lewy body ,Parkinson disease ,Unified Staging System for Lewy Body Disorders ,Neurology & Neurosurgery ,Clinical sciences - Abstract
This study was designed to correlate clinical findings with the extent of pathologic a-synuclein (aSyn) in the brain using the Unified Staging System for Lewy Body disorders (USSLB). Data from 280 cases from the Arizona Study of Aging and Neurodegenerative Disorders are presented. Each case had a complete USSLB staging and at least 1 full research clinical assessment, including subspecialty neurologist-administered movement and cognitive evaluation. Of the 280, 25.7% were cognitively normal, 8.6% had mild cognitive impairment, and 65.7% had dementia. All cases could be categorized into 1 of 5 USSLB stages (8.6% stage I-olfactory bulb only; 15.4% IIa-brainstem predominant; 13.6% IIb-limbic predominant; 31.8% III-brainstem and limbic; and 30.7% IV-neocortical) yet using the Braak staging system 70 cases (25.3%) could not be classified. Those with USSLB stages III and IV died at a younger age. Multiple measures of motor parkinsonism, cognitive impairment, hyposmia, and probable RBD were significantly correlated with increasing USSLB stage. We conclude that the USSLB is the most comprehensive staging system for all Lewy body disorders and allows for categorization and ranking of all brains with significant correlations to many motor and nonmotor clinical signs and symptoms.
- Published
- 2019
18. Risk of Parkinson's disease dementia related to level I MDS PD‐MCI
- Author
-
Hoogland, Jeroen, Boel, Judith A, Bie, Rob MA, Schmand, Ben A, Geskus, Ronald B, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Weintraub, Daniel, Junque, Carmen, Pedersen, Kenn F, Mollenhauer, Brit, Goldman, Jennifer G, Tröster, Alexander I, Burn, David J, Litvan, Irene, Geurtsen, Gert J, and Disease”, on behalf of the MDS Study Group Validation of Mild Cognitive Impairment in Parkinson
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Aging ,Prevention ,Acquired Cognitive Impairment ,Dementia ,Behavioral and Social Science ,Clinical Research ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Brain Disorders ,Parkinson's Disease ,Alzheimer's Disease ,Neurodegenerative ,Neurological ,Age Factors ,Aged ,Cognitive Dysfunction ,Female ,Humans ,Male ,Middle Aged ,Neuropsychological Tests ,Parkinson Disease ,Risk Factors ,Sex Factors ,dementia ,mild cognitive impairment ,neuropsychological tests ,Parkinson's disease ,survival analysis ,MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease” ,Human Movement and Sports Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
BackgroundThe International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.MethodsWe analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia.ResultsLevel I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia.ConclusionsLevel I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria. © 2019 International Parkinson and Movement Disorder Society.
- Published
- 2019
19. Tau immunoreactivity in peripheral tissues of human aging and select tauopathies
- Author
-
Dugger, Brittany N, Hoffman, Brittany R, Scroggins, Alex, Serrano, Geidy E, Adler, Charles H, Shill, Holly A, Belden, Christine M, Sabbagh, Marwan N, Caviness, John N, Driver Dunckley, Erika, and Beach, Thomas G
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Aging ,Brain Disorders ,Acquired Cognitive Impairment ,Neurosciences ,Dementia ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Alzheimer's Disease ,Neurodegenerative ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Aged ,Aged ,80 and over ,Alzheimer Disease ,Brain ,Female ,Humans ,Immunohistochemistry ,Male ,Neurofibrillary Tangles ,Neurons ,Tauopathies ,tau Proteins ,Propagation ,Spread ,Submandibular gland ,Skin ,Colon ,AT8 ,Psychology ,Cognitive Sciences ,Biochemistry and cell biology ,Biological psychology - Abstract
Many studies have been directed at understanding mechanisms of tau aggregation and therapeutics, nearly all focusing on the brain. It is critical to understand the presence of tau in peripheral tissues since this may provide new insights into disease progression and selective vulnerability. The current study sought to determine the presence of select tau species in peripheral tissues in elderly individuals and across an array of tauopathies. Using formalin fixed paraffin embedded sections, we examined abdominal skin, submandibular gland, and sigmoid colon among 69 clinicopathologically defined cases: 19 lacking a clinical neuropathological diagnosis (normal controls), 26 progressive supranuclear palsy (PSP), 21 Alzheimer's disease (AD), and 3 with corticobasal degeneration (CBD). Immunohistochemistry was performed using antibodies for "total" tau (HT7) and two phosphorylated tau species (AT8 and pT231). HT7 staining of abdominal skin revealed immunoreactivity of potential nerve elements in 5% of cases (1 AD, 1 AD/PSP, and 1 CBD out of 55 cases examined); skin sections lacked AT8 and pT231 immunoreactive nerve elements. Submandibular glands from all cases had HT7 immunoreactive nerve elements; while pT231 was present in 92% of cases, and AT8 in only 3 cases (2 AD and one AD/PSP case). In sigmoid colon, HT7 immunoreactivity was present in all but 2 cases (97%), pT231 in 54%, and AT8 was present in only 5/62 cases (8%). These data suggest select tau species in CNS tauopathies do not have a high propensity to spread to the periphery and this may hold clues for the understanding of CNS tau pathogenicity and vulnerability.
- Published
- 2019
20. Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study
- Author
-
Savica, Rodolfo, Beach, Thomas G, Hentz, Joseph G, Sabbagh, Marwan N, Serrano, Geidy E, Sue, Lucia I, Dugger, Brittany N, Shill, Holly A, Driver‐Dunckley, Erika, Caviness, John N, Mehta, Shyamal H, Jacobson, Sandra A, Belden, Christine M, Davis, Kathryn J, Zamrini, Edward, Shprecher, David R, and Adler, Charles H
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Dementia ,Acquired Cognitive Impairment ,Alzheimer's Disease ,Neurodegenerative ,Brain Disorders ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Aging ,Lewy Body Dementia ,2.1 Biological and endogenous factors ,Detection ,screening and diagnosis ,Aetiology ,4.1 Discovery and preclinical testing of markers and technologies ,Neurological ,Aged ,Aged ,80 and over ,Alzheimer Disease ,Brain ,Databases ,Factual ,Female ,Humans ,Lewy Bodies ,Male ,Neuropsychological Tests ,Prospective Studies ,Psychiatric Status Rating Scales ,Alzheimer's disease ,Lewy bodies ,neuropsychology ,pathology ,Neurology & Neurosurgery ,Clinical sciences - Abstract
ObjectiveIdentify clinical features predictive of Lewy body pathology in Alzheimer's disease (AD) patients in an ongoing longitudinal clinicopathologic study.Material and methodsWe queried the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) database for dementia cases with AD pathology (1997-2015). Subjects received longitudinal comprehensive clinical evaluations including motor/neuropsychological assessment and Apo-E4 genotyping. All cases were autopsied and had standard neuropathological assessments for AD and Lewy-type synucleinopathy (LTS). Subjects were categorized based on standardized pathological criteria with AD cases that had LTS but did not meet DLB pathologic criteria being categorized as ADLB. We performed pairwise comparison between the different diagnoses and multivariable modelling to identify clinical symptoms that predict the pathological diagnosis.ResultsWe identified 32 DLB/AD, 54 ADLB, 70 AD only and 41 PDD/AD cases. AD subjects with LTS pathology had higher UPDRS II and III total scores as well as generally higher individual scores compared to AD alone. While depression scales and Trail-making Test A correlated significantly with LTS, other neuropsychological variables were not significantly different. Apo E4 occurrence was similar in all groups (40%-49%).ConclusionsOur study suggests that the presence (or absence) of LTS influences motor and non-motor clinical findings in AD patients. These findings may lead to biomarkers that allow for more targeted treatment of AD.
- Published
- 2019
21. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests
- Author
-
Hoogland, Jeroen, van Wanrooij, Lennard L, Boel, Judith A, Goldman, Jennifer G, Stebbins, Glenn T, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Junque, Carme, Pedersen, Kenn F, Mollenhauer, Brit, Zabetian, Cyrus P, Eslinger, Paul J, Lewis, Simon JG, Wu, Ruey‐Meei, Klein, Martin, Rodriguez‐Oroz, Maria C, Cammisuli, Davide M, Barone, Paolo, Biundo, Roberta, de Bie, Rob MA, Schmand, Ben A, Tröster, Alexander I, Burn, David J, Litvan, Irene, Filoteo, J Vincent, Geurtsen, Gert J, Weintraub, Daniel, and Disease”, on behalf of the IPMDS Study Group Validation of Mild Cognitive Impairment in Parkinson
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Brain Disorders ,Mental Health ,Behavioral and Social Science ,Dementia ,Neurodegenerative ,Acquired Cognitive Impairment ,Aging ,Clinical Research ,Parkinson's Disease ,Neurological ,Aged ,Cognitive Dysfunction ,Databases ,Bibliographic ,Female ,Humans ,Male ,Middle Aged ,Neuropsychological Tests ,Parkinson Disease ,Parkinson disease ,MCI ,mild cognitive impairment ,cognition ,neuropsychological ,IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease” ,Human Movement and Sports Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
BackgroundNumerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies.MethodsData from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2-step meta-analytic approach using standardized scores compared performance in PD with normative data.ResultsPooled estimates of the differences between PD and site-specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between-study variability that could not be accounted for and led to inconclusive results.ConclusionsNormed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site-specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests. © 2018 International Parkinson and Movement Disorder Society.
- Published
- 2018
22. Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
- Author
-
Hall, Sara, Orrù, Christina D., Serrano, Geidy E., Galasko, Douglas, Hughson, Andrew G., Groveman, Bradley R., Adler, Charles H., Beach, Thomas G., Caughey, Byron, and Hansson, Oskar
- Published
- 2022
- Full Text
- View/download PDF
23. Antemortem detection of Parkinson’s disease pathology in peripheral biopsies using artificial intelligence
- Author
-
Signaevsky, Maxim, Marami, Bahram, Prastawa, Marcel, Tabish, Nabil, Iida, Megan A., Zhang, Xiang Fu, Sawyer, Mary, Duran, Israel, Koenigsberg, Daniel G., Bryce, Clare H., Chahine, Lana M., Mollenhauer, Brit, Mosovsky, Sherri, Riley, Lindsey, Dave, Kuldip D., Eberling, Jamie, Coffey, Chris S., Adler, Charles H., Serrano, Geidy E., White, III, Charles L., Koll, John, Fernandez, Gerardo, Zeineh, Jack, Cordon-Cardo, Carlos, Beach, Thomas G., and Crary, John F.
- Published
- 2022
- Full Text
- View/download PDF
24. Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis.
- Author
-
Shprecher, David R, Adler, Charles H, Zhang, Nan, Hentz, Joseph G, Serrano, Geidy E, Dugger, Brittany N, Shill, Holly A, Savica, Rodolfo, Caviness, John N, Sabbagh, Marwan N, Belden, Christine M, Driver-Dunckley, Erika, Mehta, Shyamal H, Sue, Lucia I, Davis, Kathryn J, Zamrini, Edward, and Beach, Thomas G
- Subjects
Humans ,Lewy Body Disease ,Supranuclear Palsy ,Progressive ,REM Sleep Behavior Disorder ,Statistics ,Nonparametric ,Aged ,Aged ,80 and over ,Female ,Male ,alpha-Synuclein ,Surveys and Questionnaires ,Dementia with Lewy bodies ,Parkinson disease ,Parkinson disease dementia ,REM sleep behavior disorder ,Neurosciences ,Brain Disorders ,Behavioral and Social Science ,Parkinson's Disease ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Sleep Research ,Dementia ,Acquired Cognitive Impairment ,Neurodegenerative ,Aging ,Clinical Research ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Neurological ,Clinical Sciences ,Cognitive Sciences ,Neurology & Neurosurgery - Abstract
Inability to accurately diagnose Lewy type alpha-synucleinopathy (LTS) pre-mortem has been a major obstacle to clinical care and research. Probable REM sleep behavior disorder (PRBD) diagnosed with support of instruments such as the Mayo Sleep Questionnaire (MSQ) may provide a cost effective means of predicting LTS. Since 2007, 602 subjects in the Arizona Study of Aging and Neurodegenerative Disorders had clinician assessment for PRBD (298 with, 304 without support of the MSQ), completed cognitive and movement examinations, and had neuropathological assessment. Mean age at death was 84.8 years. Histological evidence of LTS was found in 80/101(79.2%) cases with PRBD and 198/501 (39.5%) without PRBD (p
- Published
- 2018
25. Movement disorder society criteria for clinically established early Parkinson's disease
- Author
-
Berg, Daniela, Adler, Charles H, Bloem, Bastiaan R, Chan, Piu, Gasser, Thomas, Goetz, Christopher G, Halliday, Glenda, Lang, Anthony E, Lewis, Simon, Li, Yuan, Liepelt‐Scarfone, Inga, Litvan, Irene, Marek, Kenneth, Maetzler, Corina, Mi, Taomian, Obeso, José, Oertel, Wolfgang, Olanow, C Warren, Poewe, Werner, Rios‐Romenets, Silvia, Schäffer, Eva, Seppi, Klaus, Heim, Beatrice, Slow, Elizabeth, Stern, Matthew, Bledsoe, Ian O, Deuschl, Günther, and Postuma, Ronald B
- Subjects
Neurodegenerative ,Neurosciences ,Brain Disorders ,Aging ,Prevention ,Parkinson's Disease ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Aged ,Female ,Humans ,International Cooperation ,Male ,Middle Aged ,Parkinson Disease ,Reproducibility of Results ,Sensitivity and Specificity ,Severity of Illness Index ,Societies ,Medical ,Parkinson's disease ,diagnosis ,criteria ,Clinical Sciences ,Human Movement and Sports Sciences ,Neurology & Neurosurgery - Abstract
BackgroundIn 2015, the International Parkinson and Movement Disorder Society published clinical diagnostic criteria for Parkinson's disease (PD). Although recent validation studies suggest high accuracy, one unmet need is for highly specific criteria for clinical trials in early/de novo PD.ObjectivesThe objective of this study was to generate and test a PD diagnostic criteria termed "clinically established early PD."MethodsWe modified the Movement Disorder Society criteria to increase specificity for early PD by removing all disease duration components and changing red flags to absolute exclusions. We then estimated the sensitivity/specificity of clinically established early PD criteria in patients with disease duration
- Published
- 2018
26. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
- Author
-
Isaacson, Stuart H, Fahn, Stanley, Pahwa, Rajesh, Tanner, Caroline M, Espay, Alberto J, Trenkwalder, Claudia, Adler, Charles H, Patni, Rajiv, and Johnson, Reed
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Clinical Sciences ,Brain Disorders ,Clinical Research ,Parkinson's Disease ,Aging ,Neurodegenerative ,Clinical Trials and Supportive Activities ,Neurosciences ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Neurological ,dyskinesia ,amantadine ,Parkinson's disease ,levodopa-induced ,levodopa‐induced ,Clinical sciences - Abstract
BackgroundADS-5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS-5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, but suboptimal durability and tolerability limit its clinical utility.MethodsIn an ongoing, open-label, phase 3 study in the US and Western Europe (NCT02202551), patients with PD received 274 mg of ADS-5102 (equivalent to 340 mg amantadine HCl) once daily at bedtime for up to two years. Study outcomes included safety and assessment of motor complications, as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV. This manuscript focuses on those patients switched to ADS-5102 from amantadine IR. Results in two groups of patients who previously completed a randomized controlled trial (EASE LID or EASE LID 3) are also presented according to use of ADS-5102 or placebo in that study before enrollment in the open-label study.ResultsChange in MDS-UPDRS Part IV at week 8 was -0.3 in the previous ADS-5102 subgroup (n = 61), -3.4 in the previous placebo subgroup (n = 79), and -3.4 in the previous amantadine IR subgroup (n = 32). Effects were maintained to week 64. In the previous amantadine IR subgroup (mean treatment duration, 2.5 years), mean amantadine IR dose was 221 mg. Safety data were consistent with previous randomized controlled trials of ADS-5102.ConclusionThese open-label data suggest ADS-5102 provides incremental reduction from baseline in MDS-UDPRS Part IV score in patients switched directly from amantadine IR, without exacerbating adverse events.
- Published
- 2018
27. Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?
- Author
-
Gupta, Harsh V, Mehta, Shyamal H, Zhang, Nan, Hentz, Joseph G, Shill, Holly A, Driver‐Dunckley, Erika, Sabbagh, Marwan N, Belden, Christine M, Dugger, Brittany N, Beach, Thomas G, Serrano, Geidy E, Sue, Lucia I, Davis, Kathryn, and Adler, Charles H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Aging ,Neurosciences ,Clinical Research ,Parkinson's Disease ,Brain Disorders ,Neurodegenerative ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Neurological ,Parkinson's disease ,diagnosis certainty ,neuropathology ,Clinical sciences - Abstract
BackgroundClinical diagnostic criteria for PD rely on rest tremor, bradykinesia, and rigidity. These features are non-specific and neuropathological confirmation remains the gold standard for diagnosis. This study presents data on clinical certainty ratings in autopsy-proven PD.MethodsSubjects were assessed annually by a movement disorders specialist and assigned to a clinical certainty group for PD based on multiple clinical features before autopsy. The three groups considered for analysis are as follows: Group I 0-49% certainty, Group II 50-89% certainty, and Group III 90-100% certainty. All subjects were autopsied and had a standardized neuropathological assessment.Results275 subjects were assigned a PD certainty at their last visit before death. Group I had 80 subjects, Group II 56 subjects, and Group III 139 subjects. The clinical features recorded in Group I, II, and III, were as follows: rest tremor, bradykinesia, rigidity, postural instability, asymmetric onset, persistent asymmetry, current response to dopaminergic treatment, motor fluctuations, and dyskinesia. Rigidity, postural instability, asymmetric onset, current response to dopaminergic treatment, motor fluctuation, and dyskinesia were more likely to be present in the group which was rated with higher certainty. The final diagnosis of PD was confirmed by neuropathological assessment in 85% of the patients in Group III as compared to 30% in Group II and 5% in Group I.ConclusionsHigh certainty (90-100%) had strong positive predictive value (85%) for autopsy-proven PD as compared to either lower certainty groups (0-49% and 50-89%) which had lower predictive value (5% and 30% respectively).
- Published
- 2018
28. Conjugal Synucleinopathies: A Clinicopathologic Study
- Author
-
Adler, Charles H., primary, Halverson, Matthew, additional, Zhang, Nan, additional, Shill, Holly A., additional, Driver‐Dunckley, Erika, additional, Mehta, Shyamal H., additional, Atri, Alireza, additional, Caviness, John N., additional, Serrano, Geidy E., additional, Shprecher, David R., additional, Belden, Christine M., additional, Sabbagh, Marwan N., additional, Long, Kathy, additional, and Beach, Thomas G., additional
- Published
- 2024
- Full Text
- View/download PDF
29. Brain morphometry in former American football players: Findings from the DIAGNOSE CTE research project
- Author
-
Arciniega, Hector, primary, Baucom, Zachary H, additional, Tuz-Zahra, Fatima, additional, Tripodis, Yorghos, additional, John, Omar, additional, Carrington, Holly, additional, Kim, Nicholas, additional, Knyazhanskaya, Evdokiya E, additional, Jung, Leonard B, additional, Breedlove, Katherine, additional, Wiegand, Tim L T, additional, Daneshvar, Daniel H, additional, Rushmore, R Jarrett, additional, Billah, Tashrif, additional, Pasternak, Ofer, additional, Coleman, Michael J, additional, Adler, Charles H, additional, Bernick, Charles, additional, Balcer, Laura J, additional, Alosco, Michael L, additional, Koerte, Inga K, additional, Lin, Alexander P, additional, Cummings, Jeffrey L, additional, Reiman, Eric M, additional, Stern, Robert A, additional, Shenton, Martha E, additional, and Bouix, Sylvain, additional
- Published
- 2024
- Full Text
- View/download PDF
30. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder
- Author
-
Miglis, Mitchell G, Adler, Charles H, Antelmi, Elena, Arnaldi, Dario, Baldelli, Luca, Boeve, Bradley F, Cesari, Matteo, Dall'Antonia, Irene, Diederich, Nico J, Doppler, Kathrin, Dušek, Petr, Ferri, Raffaele, Gagnon, Jean-François, Gan-Or, Ziv, Hermann, Wiebke, Högl, Birgit, Hu, Michele T, Iranzo, Alex, Janzen, Annette, Kuzkina, Anastasia, Lee, Jee-Young, Leenders, Klaus L, Lewis, Simon J G, Liguori, Claudio, Liu, Jun, Lo, Christine, Ehgoetz Martens, Kaylena A, Nepozitek, Jiri, Plazzi, Giuseppe, Provini, Federica, Puligheddu, Monica, Rolinski, Michal, Rusz, Jan, Stefani, Ambra, Summers, Rebekah L S, Yoo, Dallah, Zitser, Jennifer, and Oertel, Wolfgang H
- Published
- 2021
- Full Text
- View/download PDF
31. Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype
- Author
-
Gerkin, Richard C, Adler, Charles H, Hentz, Joseph G, Shill, Holly A, Driver‐Dunckley, Erika, Mehta, Shyamal H, Sabbagh, Marwan N, Caviness, John N, Dugger, Brittany N, Serrano, Geidy, Belden, Christine, Smith, Brian H, Sue, Lucia, Davis, Kathryn J, Zamrini, Edward, and Beach, Thomas G
- Subjects
Biological Psychology ,Psychology ,Parkinson's Disease ,Dementia ,Prevention ,Neurodegenerative ,Acquired Cognitive Impairment ,Clinical Research ,Brain Disorders ,Aging ,Neurosciences ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Neurological ,Clinical Sciences ,Clinical and health psychology - Abstract
ObjectiveTo assess the predictive potential of the complete response pattern from the University of Pennsylvania Smell Identification Test for the diagnosis of Parkinson's disease.MethodsWe analyzed a large dataset from the Arizona Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study of health and disease in elderly volunteers. Using the complete pattern of responses to all 40 items in each subject's test, we built predictive models of neurodegenerative disease, and we validated these models out of sample by comparing model predictions against postmortem pathological diagnosis.ResultsConsistent with anatomical considerations, we found that the specific test response pattern had additional predictive power compared with a conventional measure - total test score - in Parkinson's disease, but not Alzheimer's disease. We also identified specific test questions that carry the greatest predictive power for disease diagnosis.InterpretationOlfactory ability has typically been assessed with either self-report or total score on a multiple choice test. We showed that a more accurate clinical diagnosis can be made using the pattern of responses to all the test questions, and validated this against the "gold standard" of pathological diagnosis. Information in the response pattern also suggests specific modifications to the standard test that may optimize predictive power under the typical clinical constraint of limited time. We recommend that future studies retain the individual item responses for each subject, and not just the total score, both to enable more accurate diagnosis and to enable additional future insights.
- Published
- 2017
32. Mild cognitive impairment as a risk factor for Parkinson's disease dementia
- Author
-
Hoogland, Jeroen, Boel, Judith A, Bie, Rob MA, Geskus, Ronald B, Schmand, Ben A, Dalrymple‐Alford, John C, Marras, Connie, Adler, Charles H, Goldman, Jennifer G, Tröster, Alexander I, Burn, David J, Litvan, Irene, Geurtsen, Gert J, and Disease”, on behalf of the MDS Study Group Validation of Mild Cognitive Impairment in Parkinson
- Subjects
Aging ,Behavioral and Social Science ,Parkinson's Disease ,Neurosciences ,Rehabilitation ,Neurodegenerative ,Brain Disorders ,Acquired Cognitive Impairment ,Clinical Research ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Alzheimer's Disease ,Dementia ,2.1 Biological and endogenous factors ,Aetiology ,Neurological ,Adult ,Aged ,Aged ,80 and over ,Cognitive Dysfunction ,Disease Progression ,Female ,Follow-Up Studies ,Humans ,Male ,Middle Aged ,Parkinson Disease ,Risk Factors ,Severity of Illness Index ,Parkinson's disease ,mild cognitive impairment ,dementia ,neuropsychological tests ,survival analyses ,MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease” ,Clinical Sciences ,Human Movement and Sports Sciences ,Neurology & Neurosurgery - Abstract
BackgroundThe International Parkinson and Movement Disorder Society criteria for mild cognitive impairment in PD were recently formulated.ObjectivesThe aim of this international study was to evaluate the predictive validity of the comprehensive (level II) version of these criteria by assessment of their contribution to the hazard of PD dementia.MethodsIndividual patient data were selected from four separate studies on cognition in PD that provided information on demographics, motor examination, depression, neuropsychological examination suitable for application of level II criteria, and longitudinal follow-up for conversion to dementia. Survival analysis evaluated the predictive value of level II criteria for cognitive decline toward dementia as expressed by the relative hazard of dementia.ResultsA total of 467 patients were included. The analyses showed a clear contribution of impairment according to level II mild cognitive impairment criteria, age, and severity of PD motor symptoms to the hazard of dementia. There was a trend of increasing hazard of dementia with declining neuropsychological performance.ConclusionsThis is the first large international study evaluating the predictive validity of level II mild cognitive impairment criteria for PD. The results showed a clear and unique contribution of classification according to level II criteria to the hazard of PD dementia. This finding supports their predictive validity and shows that they contribute important new information on the hazard of dementia, beyond known demographic and PD-specific factors of influence. © 2017 International Parkinson and Movement Disorder Society.
- Published
- 2017
33. It's tricky: Rating alleviating maneuvers in cervical dystonia
- Author
-
Cisneros, Elizabeth, Stebbins, Glenn T., Chen, Qiyu, Vu, Jeanne P., Benadof, Casey N., Zhang, Zheng, Barbano, Richard L., Fox, Susan H., Goetz, Christopher G., Jankovic, Joseph, Jinnah, Hyder A., Perlmutter, Joel S., Adler, Charles H., Factor, Stewart A., Reich, Stephen G., Rodriguez, Ramon, Severt, Lawrence L., Stover, Natividad P., Berman, Brian D., Comella, Cynthia L., and Peterson, David A.
- Published
- 2020
- Full Text
- View/download PDF
34. Dystonic Golfer's cramp: Pilot study of propranolol and looking at the hole
- Author
-
Adler, Charles H., Zhang, Nan, Crews, Debra, McDaniel, Troy, Tucker, Jennifer, Marquardt, Christian, and Caviness, John N.
- Published
- 2020
- Full Text
- View/download PDF
35. Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.
- Author
-
Jackson, Lauren M., Woodruff, Bryan K., Tremblay, Cecilia, Shill, Holly A., Beach, Thomas G., Serrano, Geidy E., and Adler, Charles H.
- Subjects
PARKINSON'S disease ,CEREBRAL amyloid angiopathy ,DARDARIN ,ALZHEIMER'S disease ,NEUROFIBRILLARY tangles ,SUBSTANTIA nigra - Abstract
Background: The G2019S leucine‐rich repeat kinase 2 (LRRK2) gene mutation is an important and commonly found genetic determinant of Parkinson's disease (PD). The neuropathological findings associated with this mutation have thus far been varied but are most often associated with Lewy body (LB) pathology. Objective: Describe a case of clinical Parkinson's disease with levodopa responsiveness found to have LRRK2 mutations and the absence of Lewy bodies. Method: We present an 89‐year‐old man with a 10‐year history of slowly progressive parkinsonism suspected to be secondary to Parkinson's disease. Results: Neuropathological evaluation revealed nigral degeneration without Lewy bodies or Lewy neurites, but there were frequent tau‐immunopositive neurites and astrocytes in the putamen and substantia nigra, neocortical glial tau positive astrocytes associated with aging‐related tau astrogliopathy (ARTAG), as well as neurofibrillary tangles, beta amyloid plaques, and amyloid angiopathy typical of advanced Alzheimer's disease. G2019S LRRK2 homozygous mutations were found. Conclusion: This case illustrates that levodopa‐responsive clinical PD caused by G2019S LRRK2 mutations can occur without Lewy bodies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Analgesia in Transcutaneous Laryngeal Botulinum Toxin Injections: A Randomized Crossover Trial.
- Author
-
Heyes, Richard, Adler, Charles H., Yee, Claire, Lott, David G., and Karle, William E.
- Abstract
Objectives: There is an absence of data in the literature regarding methods to improve the patient experience during the performance of awake in‐office laryngeal injections. This study sought to evaluate whether the use of local anesthetic or a vibrating instrument decreased overall pain experienced by patients with laryngeal dystonia, frequently referred to as spasmodic dysphonia (SD), undergoing transcervical botulinum toxin injections. Methods: This was an unblinded, prospective randomized control trial with a crossover design where each patient received transcutaneous transcricothyroid injection of botulinum toxin with alternating use of no anesthesia, local anesthesia (2% lidocaine in 1:100,000 epinephrine), and vibrating instrument in three consecutive laryngeal injections to treat adductor SD. Patients were randomized to the order they received these treatments. Patients measured pain on a 0–10 visual analogue scale (VAS) and selected their preferred technique after receiving all three analgesic modalities. Results: Thirty‐two patients completed the study. There was no statistically significant difference in pain between the three analgesic techniques (p = 0.38). The most preferred analgesic technique was the vibrating wand (44% (14/32)). Lidocaine was the second most preferred (37% (12/32)) and 19% (6/32) of patients preferred nothing. When combining the wand and nothing groups, 63% of patients preferred one of these two methods (95% exact CI: 44%–79%). Conclusion: There was no statistically significant difference in median pain experienced by patients during laryngeal botulinum toxin injection between these different analgesic modalities. More than half of the patients selected a preference for a technique that did not include lidocaine. This data supports individualization of analgesia during transcutaneous laryngeal injections. Level of Evidence: 2 Laryngoscope, 134:2277–2281, 2024 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Do Parkinson disease subject and caregiver-reported Epworth sleepiness scale reponses correlate?
- Author
-
Shprecher, David R., Adler, Charles H., Zhang, Nan, Shill, Holly A., Belden, Christine M., Driver-Dunckley, Erika, Mehta, Shyamal H., Davis, Kathryn J., Sue, Lucia I., Zamrini, Edward, and Beach, Thomas G.
- Published
- 2020
- Full Text
- View/download PDF
38. Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings
- Author
-
Adler, Charles H, Dugger, Brittany N, Hentz, Joseph G, Hinni, Michael L, Lott, David G, Driver-Dunckley, Erika, Mehta, Shyamal, Serrano, Geidy, Sue, Lucia I, Duffy, Amy, Intorcia, Anthony, Filon, Jessica, Pullen, Joel, Walker, Douglas G, and Beach, Thomas G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Neurodegenerative ,Aging ,Clinical Research ,Digestive Diseases ,Neurosciences ,Brain Disorders ,Parkinson's Disease ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Aged ,Biopsy ,Needle ,Female ,Humans ,Male ,Middle Aged ,Parkinson Disease ,Submandibular Gland ,alpha-Synuclein ,Parkinson's disease ,submandibular gland ,biopsy ,synuclein ,Human Movement and Sports Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
IntroductionFinding a peripheral tissue biopsy site to diagnose early PD would be of value for clinical care, biomarker validation, and as research enrollment criteria. Whereas autopsy and advanced PD studies suggest that the submandibular gland is an important biopsy site, there are no studies in early PD. The aim of this study was to determine whether needle biopsy of the submandibular gland reveals Lewy type alpha-synucleinopathy in early PD.MethodsTwenty-five early PD (duration
- Published
- 2016
39. Prevalence of Submandibular Gland Synucleinopathy in Parkinson’s Disease, Dementia with Lewy Bodies and other Lewy Body Disorders
- Author
-
Beach, Thomas G, Adler, Charles H, Serrano, Geidy, Sue, Lucia I, Walker, DG, Dugger, Brittany N, Shill, Holly A, Driver-Dunckley, Erika, Caviness, John N, Intorcia, Anthony, Filon, Jessica, Scott, Sarah, Garcia, Angelica, Hoffman, Brittany, Belden, Christine M, Davis, Kathryn J, and Sabbagh, Marwan N
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Aging ,Brain Disorders ,Acquired Cognitive Impairment ,Neurodegenerative ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Parkinson's Disease ,Clinical Research ,Lewy Body Dementia ,Dementia ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Aged ,Aged ,80 and over ,Autopsy ,Early Diagnosis ,Female ,Humans ,Immunohistochemistry ,Lewy Body Disease ,Male ,Parkinson Disease ,Prevalence ,Submandibular Gland Diseases ,alpha-Synuclein ,Biopsy ,diagnosis ,clinical trial ,biomarker ,pathology ,therapy ,Arizona Parkinson's Disease Consortium ,Biochemistry and Cell Biology - Abstract
BackgroundClinical misdiagnosis, particularly at early disease stages, is a roadblock to finding new therapies for Lewy body disorders. Biopsy of a peripheral site might provide improved diagnostic accuracy. Previously, we reported, from both autopsy and needle biopsy, a high prevalence of submandibular gland synucleinopathy in Parkinson's disease (PD). Here, we report on an extension of these studies to subjects with dementia with Lewy bodies (DLB) and other Lewy body disorders in 228 autopsied subjects from the Arizona Study of Aging and Neurodegenerative Disorders.ObjectiveTo provide an estimate of the prevalence of histological synucleinopathy in the submandibular glands of subjects with PD and other Lewy body disorders.MethodsSubmandibular gland sections from autopsied subjects were stained with an immunohistochemical method for α-synuclein phosphorylated at serine 129. Included were 146 cases with CNS Lewy-type synucleinopathy (LTS), composed of 46 PD, 28 DLB, 14 incidental Lewy body disease (ILBD), 33 Alzheimer's disease with Lewy bodies (ADLB) and 2 with progressive supranuclear palsy and Lewy bodies (PSPLB). Control subjects included 79 normal elderly, 15 AD, 12 PSP, 2 conticobasal degeneration (CBD) and 2 multiple system atrophy (MSA).ResultsSubmandibular gland LTS was found in 42/47 (89%) of the PD subjects, 20/28 (71%) DLB, 4/33 (12%) ADLB and 1/9 (11%) ILBD subjects but none of the 110 control subjects.ConclusionsThese results provide support for further clinical trials of in vivo submandibular gland diagnostic biopsy for PD and DLB. An accurate peripheral biopsy diagnosis would assist subject selection for clinical trials and could also be used to verify other biomarkers.
- Published
- 2016
40. A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease
- Author
-
Cardoso, Francisco, primary, Goetz, Christopher G., additional, Mestre, Tiago A., additional, Sampaio, Cristina, additional, Adler, Charles H., additional, Berg, Daniela, additional, Bloem, Bastiaan R., additional, Burn, David J., additional, Fitts, Michael S., additional, Gasser, Thomas, additional, Klein, Christine, additional, de Tijssen, Marina A.J., additional, Lang, Anthony E., additional, Lim, Shen‐Yang, additional, Litvan, Irene, additional, Meissner, Wassilios G., additional, Mollenhauer, Brit, additional, Okubadejo, Njideka, additional, Okun, Michael S., additional, Postuma, Ronald B., additional, Svenningsson, Per, additional, Tan, Louis C.S., additional, Tsunemi, Taiji, additional, Wahlstrom‐Helgren, Sarah, additional, Gershanik, Oscar S., additional, Fung, Victor S.C., additional, and Trenkwalder, Claudia, additional
- Published
- 2023
- Full Text
- View/download PDF
41. Disease progression modelling reveals heterogeneity in trajectories of Lewy-type alpha-synuclein pathology
- Author
-
Mastenbroek, Sophie E, primary, Vogel, Jacob W, additional, Collij, Lyduine E, additional, Serrano, Geidy E, additional, Tremblay, Cecilia, additional, Young, Alexandra L, additional, Arce, Richard A, additional, Shill, Holly A, additional, Driver-Dunckley, Erika D, additional, Mehta, Shyamal H, additional, Belden, Christine M, additional, Atri, Alireza, additional, Choudhury, Parichita, additional, Barkhof, Frederik, additional, Adler, Charles H, additional, Ossenkoppele, Rik, additional, Beach, Thomas G, additional, and Hansson, Oskar, additional
- Published
- 2023
- Full Text
- View/download PDF
42. Clinical Characteristics and Outcomes in Young‐Onset Multiple System Atrophy
- Author
-
Badihian, Negin, primary, Savica, Rodolfo, additional, Adler, Charles H., additional, Wszolek, Zbigniew K., additional, Jackson, Lauren M., additional, Benarroch, Eduardo E., additional, Sandroni, Paola, additional, Low, Phillip A., additional, Singer, Wolfgang, additional, and Coon, Elizabeth A., additional
- Published
- 2023
- Full Text
- View/download PDF
43. α-synuclein seed amplification in Parkinson‘s disease
- Author
-
Beach, Thomas G, primary, Adler, Charles H, additional, Shill, Holly A, additional, Serrano, Geidy E, additional, and Zhang, Nan, additional
- Published
- 2023
- Full Text
- View/download PDF
44. Examination of parkinsonism in former elite American football players
- Author
-
Alosco, Michael L., primary, Adler, Charles H., additional, Dodick, David W., additional, Tripodis, Yorghos, additional, Balcer, Laura J., additional, Bernick, Charles, additional, Banks, Sarah J., additional, Barr, William B., additional, Wethe, Jennifer V., additional, Palmisano, Joseph N., additional, Martin, Brett, additional, Hartlage, Kaitlin, additional, Cantu, Robert C., additional, Geda, Yonas E., additional, Katz, Douglas I., additional, Mez, Jesse, additional, Cummings, Jeffery L., additional, Shenton, Martha E., additional, Reiman, Eric M., additional, and Stern, Robert A., additional
- Published
- 2023
- Full Text
- View/download PDF
45. 4 Risk Factor and Biomarker Correlates of FLAIR White Matter Hyperintensities in Former American Football Players
- Author
-
Ly, Monica T, primary, Tuz-Zahra, Fatima, additional, Tripodis, Yorghos, additional, Adler, Charles H, additional, Balcer, Laura J, additional, Bernick, Charles, additional, Peskind, Elaine, additional, Mariani, Megan L, additional, Au, Rhoda, additional, Banks, Sarah J, additional, Barr, William B, additional, Wethe, Jennifer V, additional, Bondi, Mark W, additional, Delano-Wood, Lisa, additional, Cantu, Robert C, additional, Coleman, Michael J, additional, Dodick, David W, additional, McClean, Michael D, additional, Mez, Jesse, additional, Palmisano, Joseph N, additional, Martin, Brett, additional, Hartlage, Kaitlin, additional, Lin, Alexander P, additional, Koerte, Inga K, additional, Cummings, Jeffrey L, additional, Reiman, Eric M, additional, Shenton, Martha E, additional, Stern, Robert A, additional, Bouix, Sylvain, additional, and Alosco, Michael L, additional
- Published
- 2023
- Full Text
- View/download PDF
46. 6 Association Between American Football Play and Parkinson's Disease: Analysis of the Fox Insight Data Set
- Author
-
Bruce, Hannah, primary, Tripodis, Yorghos, additional, McClean, Michael, additional, Korell, Monica, additional, Tanner, Caroline M, additional, Contreras, Brittany, additional, Gottesman, Joshua, additional, Kirsch, Leslie, additional, Karim, Yasir, additional, Martin, Brett, additional, Palmisano, Joseph, additional, Stein, Thor D, additional, Mez, Jesse, additional, Stern, Robert A, additional, Adler, Charles H, additional, Nowinski, Chris, additional, McKee, Ann C, additional, and Alosco, Michael L, additional
- Published
- 2023
- Full Text
- View/download PDF
47. Association of probable REM sleep behavior disorder with pathology and years of contact sports play in chronic traumatic encephalopathy
- Author
-
Adams, Jason W., Alosco, Michael L., Mez, Jesse, Alvarez, Victor E., Huber, Bertrand R., Tripodis, Yorghos, Adler, Charles H., Kubilius, Carol, Cormier, Kerry A., Mathais, Rebecca, Nicks, Raymond, Kelley, Hunter J., Saltiel, Nicole, Uretsky, Madeline, Nair, Evan, Aytan, Nurgul, Cherry, Jonathan D., Nowinski, Christopher J., Kowall, Neil W., Goldstein, Lee E., Dwyer, Brigid, Katz, Douglas I., Cantu, Robert C., Stern, Robert A., McKee, Ann C., and Stein, Thor D.
- Published
- 2020
- Full Text
- View/download PDF
48. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment
- Author
-
Dugger, Brittany N, Davis, Kathryn, Malek-Ahmadi, Michael, Hentz, Joseph G, Sandhu, Shawn, Beach, Thomas G, Adler, Charles H, Caselli, Richard J, Johnson, Travis A, Serrano, Geidy E, Shill, Holly A, Belden, Christine, Driver-Dunckley, Erika, Caviness, John N, Sue, Lucia I, Jacobson, Sandra, Powell, Jessica, and Sabbagh, Marwan N
- Subjects
Brain Disorders ,Neurosciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Alzheimer's Disease ,Neurodegenerative ,Aging ,Acquired Cognitive Impairment ,Dementia ,2.1 Biological and endogenous factors ,Aetiology ,Neurological ,Aged ,Aged ,80 and over ,Amnesia ,Brain ,Cerebral Amyloid Angiopathy ,Cerebral Infarction ,Cognitive Dysfunction ,Female ,Humans ,Leukoencephalopathies ,Lewy Bodies ,Male ,Neurofibrillary Tangles ,Parkinson Disease ,Plaque ,Amyloid ,Temporal Lobe ,Cognitive Sciences ,Neurology & Neurosurgery - Abstract
BackgroundAlthough there are studies investigating the pathologic origins of mild cognitive impairment (MCI), they have revolved around comparisons to normal elderly individuals or those with Alzheimer's disease (AD) or other dementias. There are few studies directly comparing the comprehensive neuropathology of amnestic (aMCI) and nonamnestic (naMCI) MCI.MethodsThe database of the Brain and Body Donation Program ( www.brainandbodydonationprogram.org ), a longitudinal clinicopathological study of normal aging and neurodegenerative disorders, was queried for subjects who were carrying a diagnosis of aMCI or naMCI at the time of autopsy. Neuropathological lesions, including neuritic plaques, neurofibrillary tangles (NFTs), Lewy bodies (LBs), infarcts, cerebral white matter rarefaction (CWMR), cerebral amyloid angiopathy (CAA), and concurrent major clinicopathological diagnoses, including Parkinson's disease (PD) were analyzed.ResultsThirty four subjects with aMCI and 15 naMCI met study criteria. Subjects with aMCI were older at death (88 vs. 83 years of age, p = 0.03). Individuals with naMCI had higher densities of LBs within the temporal lobe (p = 0.04) while subjects with aMCI had a propensity for increased NFTs in parietal and temporal lobes (p values = 0.07). After adjusting for age at death, the only significant difference was greater densities of temporal lobe NFTs within the aMCI group. Other regional pathology scores for plaques, NFTs, and LBs were similar between groups. Subjects met clinico-pathological criteria for co-existent PD in 24 % aMCI and 47 % naMCI while neuropathological criteria for AD were met in equal percentages of aMCI and of naMCI cases (53 %); these proportional differences were not significant (p values > 0.35). Furthermore, regardless of amnestic status, there was a greater presence of CAA (71 % of MCI with executive dysfunction vs. 39 % without p = 0.03) and a greater presence of CWMR (81 % of MCI with executive dysfunction and 54 % without p = 0.046) in MCI cases with executive dysfunction.ConclusionsNo single pathologic entity strongly dichotomized MCI groups, perhaps due to the pathologic heterogeneity found within both entities. However, these data suggest the possibility for naMCI to have a propensity for increased LBs and aMCI for increased NFTs in select anatomic regions.
- Published
- 2015
49. MDS clinical diagnostic criteria for Parkinson's disease.
- Author
-
Postuma, Ronald B, Berg, Daniela, Stern, Matthew, Poewe, Werner, Olanow, C Warren, Oertel, Wolfgang, Obeso, José, Marek, Kenneth, Litvan, Irene, Lang, Anthony E, Halliday, Glenda, Goetz, Christopher G, Gasser, Thomas, Dubois, Bruno, Chan, Piu, Bloem, Bastiaan R, Adler, Charles H, and Deuschl, Günther
- Subjects
Humans ,Parkinson Disease ,Severity of Illness Index ,Neuropsychological Tests ,Reference Standards ,Societies ,Scientific ,Parkinson's disease ,absolute exclusion criteria ,clinical diagnostic criteria ,motor parkinsonism ,non-motor manifestations ,red flags ,supportive criteria ,Neurology & Neurosurgery ,Clinical Sciences ,Human Movement and Sports Sciences ,Cognitive Sciences - Abstract
This document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances.
- Published
- 2015
50. MDS research criteria for prodromal Parkinson's disease.
- Author
-
Berg, Daniela, Postuma, Ronald B, Adler, Charles H, Bloem, Bastiaan R, Chan, Piu, Dubois, Bruno, Gasser, Thomas, Goetz, Christopher G, Halliday, Glenda, Joseph, Lawrence, Lang, Anthony E, Liepelt-Scarfone, Inga, Litvan, Irene, Marek, Kenneth, Obeso, José, Oertel, Wolfgang, Olanow, C Warren, Poewe, Werner, Stern, Matthew, and Deuschl, Günther
- Subjects
Humans ,Parkinson Disease ,Severity of Illness Index ,Societies ,Scientific ,Prodromal Symptoms ,Parkinson's disease ,diagnosis ,prodromal ,Neurology & Neurosurgery ,Clinical Sciences ,Human Movement and Sports Sciences ,Cognitive Sciences - Abstract
This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.